Cargando…

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

BACKGROUND: The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking. This study investigated characteristics, treatment sequences and clinical ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waddell, T., Fife, K., Griffiths, R., Sharma, A., Dhokia, P., Groves, L., Hurst, M., Tsang, C., Sugrue, D., McKenna, S., Houghton, J., Carroll, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169585/ https://www.ncbi.nlm.nih.gov/pubmed/35668384 http://dx.doi.org/10.1186/s12885-022-09694-y

Ejemplares similares

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
por: Choy, Ernest, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later‐line nivolumab monotherapy—The Asahikawa Gastric Cancer Cohort Study (AGCC)
por: Tanaka, Kazuyuki, et al.
Publicado: (2021)

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
por: Lu, Shun, et al.
Publicado: (2022)

Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma
por: Hori, Ryusuke, et al.
Publicado: (2019)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Research Quality—Lessons from the UK Research Excellence Framework (REF) 2021
por: Thompson, David R., et al.
Publicado: (2022)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy
por: Şen, Selçuk, et al.
Publicado: (2018)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors
por: Kawahara, Takashi, et al.
Publicado: (2022)

The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
por: Abbas, Waseem, et al.
Publicado: (2020)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
por: S. Ahmad, Saif, et al.
Publicado: (2015)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
por: Uchida, Naohiro, et al.
Publicado: (2017)

Unilateral Posterior Uveitis in a Patient Receiving Nivolumab for Malignant Melanoma
por: Giannakis, Periklis, et al.
Publicado: (2023)

Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy
por: Lee, Jungmin, et al.
Publicado: (2022)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2021)

Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dqve0d0pmct6s3ioi9598opnre